• Seattle Genetics Inc., of Bothell, Wash, said it started two Phase I trials of SGN-CD19A, which uses the firm's antibody-drug conjugate technology. Both are open-label, dose-escalation trials, one in B-cell acute lymphoblastic leukemia and the other in B-cell non-Hodgkin's lymphomas, and both are designed to assess the safety and antitumor activity of the CD19-targeted drug.